These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32180895)

  • 1. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review.
    Spanos C; Bretherton I; Zajac JD; Cheung AS
    World J Diabetes; 2020 Mar; 11(3):66-77. PubMed ID: 32180895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterising body composition and bone health in transgender individuals receiving gender-affirming hormone therapy.
    Ford K; Huggins E; Sheean P
    J Hum Nutr Diet; 2022 Dec; 35(6):1105-1114. PubMed ID: 35509260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgender healthcare: metabolic outcomes and cardiovascular risk.
    Glintborg D; Christensen LL; Andersen MS
    Diabetologia; 2024 Nov; 67(11):2393-2403. PubMed ID: 38958699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review.
    McFarlane T; Zajac JD; Cheung AS
    Clin Endocrinol (Oxf); 2018 Dec; 89(6):700-711. PubMed ID: 30107028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance in transgender individuals correlates with android fat mass.
    Bretherton I; Spanos C; Leemaqz SY; Premaratne G; Grossmann M; Zajac JD; Cheung AS
    Ther Adv Endocrinol Metab; 2021; 12():2042018820985681. PubMed ID: 33552464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis.
    Turino Miranda K; Kalenga CZ; Saad N; Dumanski SM; Collister D; Rytz CL; Lorenzetti DL; Chang DH; McClurg C; Sola DY; Ahmed SB
    Am J Physiol Heart Circ Physiol; 2022 Nov; 323(5):H861-H868. PubMed ID: 36053748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Providing Care for Transgender Persons With Kidney Disease: A Narrative Review.
    Collister D; Saad N; Christie E; Ahmed S
    Can J Kidney Health Dis; 2021; 8():2054358120985379. PubMed ID: 33552529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men.
    Pirtea P; Ayoubi JM; Desmedt S; T'Sjoen G
    Fertil Steril; 2021 Oct; 116(4):936-942. PubMed ID: 34481638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans.
    Hashemi L; Marijic Buljubasic A; Budoff MJ; Copeland LA; Jackson NJ; Jasuja GK; Gornbein J; Reue K
    JAMA Netw Open; 2024 Jul; 7(7):e2419696. PubMed ID: 38954413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Gender-Affirming Hormone Therapy on Measures of Kidney Function: A Systematic Review and Meta-Analysis.
    Krupka E; Curtis S; Ferguson T; Whitlock R; Askin N; Millar AC; Dahl M; Fung R; Ahmed SB; Tangri N; Walsh M; Collister D
    Clin J Am Soc Nephrol; 2022 Sep; 17(9):1305-1315. PubMed ID: 35973728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Outcomes Associated With Having an Oophorectomy Versus Retaining One's Ovaries for Transmasculine and Gender Diverse Individuals Treated With Testosterone Therapy: A Systematic Review.
    Kumar S; Mukherjee S; O'Dwyer C; Wassersug R; Bertin E; Mehra N; Dahl M; Genoway K; Kavanagh AG
    Sex Med Rev; 2022 Oct; 10(4):636-647. PubMed ID: 35831234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Effects of Gender-Affirming Hormone Therapy on Dysphoria and Quality of Life in Transgender Individuals: A Prospective Controlled Study.
    Foster Skewis L; Bretherton I; Leemaqz SY; Zajac JD; Cheung AS
    Front Endocrinol (Lausanne); 2021; 12():717766. PubMed ID: 34394009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Outcomes Associated With Having an Oophorectomy Versus Retaining One's Ovaries for Transmasculine and Gender Diverse Individuals Treated With Testosterone Therapy: A Systematic Review.
    Kumar S; Mukherjee S; O'Dwyer C; Wassersug R; Bertin E; Mehra N; Dahl M; Genoway K; Kavanagh AG
    Sex Med Rev; 2022 Oct; 10(4):636-647. PubMed ID: 37051961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women.
    Haupt C; Henke M; Kutschmar A; Hauser B; Baldinger S; Saenz SR; Schreiber G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013138. PubMed ID: 33251587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional ovarian reserve in transgender men receiving testosterone therapy: evidence for preserved anti-Müllerian hormone and antral follicle count under prolonged treatment.
    Yaish I; Tordjman K; Amir H; Malinger G; Salemnick Y; Shefer G; Serebro M; Azem F; Golani N; Sofer Y; Stern N; Greenman Y
    Hum Reprod; 2021 Sep; 36(10):2753-2760. PubMed ID: 34411251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body Composition and Markers of Cardiometabolic Health in Transgender Youth Compared With Cisgender Youth.
    Nokoff NJ; Scarbro SL; Moreau KL; Zeitler P; Nadeau KJ; Juarez-Colunga E; Kelsey MM
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e704-14. PubMed ID: 31544944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY.
    Chantrapanichkul P; Stevenson MO; Suppakitjanusant P; Goodman M; Tangpricha V
    Endocr Pract; 2021 Jan; 27(1):27-33. PubMed ID: 33471729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Gender-Affirming Hormone Therapy on Physical Performance.
    Cheung AS; Zwickl S; Miller K; Nolan BJ; Wong AFQ; Jones P; Eynon N
    J Clin Endocrinol Metab; 2024 Jan; 109(2):e455-e465. PubMed ID: 37437247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Type 2 Diabetes Mellitus in Transgender Individuals Undergoing Gender Affirming Hormonal Therapy: A Systematic Review.
    Panday P; Ejaz S; Gurugubelli S; Prathi SK; Palou Martinez Y; Arrey Agbor DB; Nath TS
    Cureus; 2024 Apr; 16(4):e58137. PubMed ID: 38738018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.